Metabolic interventions can also be implemented through cell therapies like GLUT5 CAR-T cells, which precisely target tumor-specific metabolic pathways while avoiding the systemic toxicity associated with metabolic interventions on normal tissues (79). The gene discussed is SLC2A5; the disease is neoplasm.